Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 161

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Open access
Mackenzie, Isla S, Hawkey, Christopher J, Ford, Ian, Greenlaw, Nicola, Pigazzani, Filippo, Rogers, Amy, Struthers, Allan D, Begg, Alan G, Wei, Li, Avery, Anthony J, Taggar, Jaspal S, Walker, Andrew, Duce, Suzanne L, Barr, Rebecca J, Dumbleton, Jennifer S, Rooke, Evelien D, Townend, Jonathan N, Ritchie, Lewis D, MacDonald, Thomas M, Ahmed, Husnat, Arthur, Peter, Aziz, Jane, Barnes, Lawrence, Boyle, Sarah, Brighton, Tom, Brown, Morris, Caulfield, Mark, Dawson, Jesse, Denvir, Martin, Doney, Alexander SF, Doshi, Sagar, Dryburgh, Moira, Eddleston, Michael, Finlayson, Jim, Fuat, Ahmet, Furnace, Jacqueline, Grieve, JW Kerr, Guthrie, Greg, Ham, Sharon, Isaard, Emma, Jennings, Claudine, Johnson, Richard, Kerr, Claire, Khan, Sohail, Krishnan, Kailash, Long, Susan, Mackintosh, Anne, Macleod, Mary Joan, McCormack, Terry, McEleny, Paul, Morar, Monique, Nadir, Adnan, Newby, David, Petrie, Colin, Preiss, David, Ralston, Stuart, Randall, Marc, Routledge, Helen, Shakir, Saad, Sharma, Raj, Shepherd, Bridget, Sims, Don, Snedden, Gordon, Trevelyan, Jasper, Weir, Christopher, Weir, Robin, Wetherall, Kirsty, Wilson, Robbie, Wilson, Adam, Zutis, Kris · 2022 · The Lancet

Abstract

BACKGROUND: Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous studies have shown that allopurinol has positive effects on several cardiovascular parameters. The ALL-HEART study aimed to determine whether allopurinol therapy improves major cardiovascular outcomes in patients with ischaemic heart disease. METHODS: ALL-HEART was a multicentre, prospective, randomised, open-label, blinded-endpoint trial done in 18 regional centres in England and Scotland, with patients recruited from 424 primary care practices. Eligible patients were aged 60 years or older, with ischaemic heart disease but no history of gout. Participants were randomly assigned (1:1), using a central web-based randomisation system accessed via a web-based application or an interactive voice response system, to receive oral allopurinol up-titrated to a dose of 600 mg daily (300 mg daily in participants with moderate renal impairment at baseline) or to continue usual care. The primary outcome was the composite cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. The hazard ratio (allopurinol vs usual care) in a Cox proportional hazards model was assessed for superiority in a modified intention-to-treat analysis (excluding randomly assigned patients later found to have met one of the exclusion criteria). The safety analysis population included all patients in the modified intention-to-treat usual care group and those who took at least one dose of randomised medication in the allopurinol group. This study is registered with the EU Clinical Trials Register, EudraCT 2013-003559-39, and ISRCTN, ISRCTN32017426. FINDINGS: Between Feb 7, 2014, and Oct 2, 2017, 5937 participants were enrolled and then randomly assigned to receive allopurinol or usual care. After exclusion of 216 patients after randomisation, 5721 participants (mean age 72·0 years [SD 6·8], 4321 [75·5%] males, and 5676 [99·2%] white) were included in the modified intention-to-treat population, with 2853 in the allopurinol group and 2868 in the usual care group. Mean follow-up time in the study was 4·8 years (1·5). There was no evidence of a difference between the randomised treatment groups in the rates of the primary endpoint. 314 (11·0%) participants in the allopurinol group (2·47 events per 100 patient-years) and 325 (11·3%) in the usual care group (2·37 events per 100 patient-years) had a primary endpoint (hazard ratio [HR] 1·04 [95% CI 0·89-1·21], p=0·65). 288 (10·1%) participants in the allopurinol group and 303 (10·6%) participants in the usual care group died from any cause (HR 1·02 [95% CI 0·87-1·20], p=0·77). INTERPRETATION: In this large, randomised clinical trial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there was no difference in the primary outcome of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death between participants randomised to allopurinol therapy and those randomised to usual care. FUNDING: UK National Institute for Health and Care Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)01657-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 161

Metadata

Authors
Mackenzie, I. S., Hawkey, C. J., Ford, I., Greenlaw, N., Pigazzani, F., Rogers, A., Struthers, A. D., Begg, A. G., Wei, L., Avery, A. J., Taggar, J. S., Walker, A., Duce, S. L., Barr, R. J., Dumbleton, J. S., Rooke, E. D., Townend, J. N., Ritchie, L. D., MacDonald, T. M., Ahmed, H., Arthur, P., Aziz, J., Barnes, L., Boyle, S., Brighton, T., Brown, M., Caulfield, M., Dawson, J., Denvir, M., Doney, A. S., Doshi, S., Dryburgh, M., Eddleston, M., Finlayson, J., Fuat, A., Furnace, J., Grieve, J. K., Guthrie, G., Ham, S., Isaard, E., Jennings, C., Johnson, R., Kerr, C., Khan, S., Krishnan, K., Long, S., Mackintosh, A., Macleod, M. J., McCormack, T., McEleny, P., Morar, M., Nadir, A., Newby, D., Petrie, C., Preiss, D., Ralston, S., Randall, M., Routledge, H., Shakir, S., Sharma, R., Shepherd, B., Sims, D., Snedden, G., Trevelyan, J., Weir, C., Weir, R., Wetherall, K., Wilson, R., Wilson, A., & Zutis, K.
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-10
Volume
400
Issue
10359
Pages
1195-1205
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4303423686
Cited by
161
References
2
FWCI
17.04
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01657-9
The paper
Mackenzie, I. S., Hawkey, C. J., Ford, I., Greenlaw, N., Pigazzani, F., Rogers, A., Struthers, A. D., Begg, A. G., Wei, L., Avery, A. J., Taggar, J. S., Walker, A., Duce, S. L., Barr, R. J., Dumbleton, J. S., Rooke, E. D., Townend, J. N., Ritchie, L. D., MacDonald, T. M., . . . Zutis, K. (2022). Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)01657-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.